Compare Merck & Co., Inc. (MRK) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SoFi Technologies Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while SoFi Technologies Inc trades at $17.39 (market cap $23.26B). The key difference: Merck & Co., Inc. is far larger — about 15.7× SoFi Technologies Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| MRK | SOFI | |
|---|---|---|
Market Cap | $366.28B | $23.26B |
Sector | Health | Financials |
52-Week High | $156.43 | $32.21 |
52-Week Low | $77.60 | $15.15 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SOFI stock trades at $18.01, down 1.15% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.12 EPS, and revenue growth remains robust at 40% year-over-year. Recent news highlights a partnership with Payward to enhance banking and digital asset connectivity, though the stock faces pressure from rising Treasury yields affecting fintech lenders.
The outlook is mixed; solid fundamentals and growth support upside toward the $20.63 consensus target, but risks include negative operating cash flow, high leverage, and macroeconomic sensitivity. Investors should weigh the company's expansion against persistent profitability challenges and competitive fintech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
